Device type · PQP
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
PQP
Pathology
Device class
Class III
FDA decisions since 2015
52
510(k), De Novo and PMA
Adverse event reports
7
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System
- Product code
- PQP
- Device class
- Class III
- Review panel
- Pathology
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for PQP
Latest FDA decisions
The 8 newest of 52 since 2015.
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- TruSight Oncology ComprehensivePMA supplement
P230011-S006 · Decided Aug 14, 2026 · 269 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Personal Genome Diagnostics, Inc.
P250036 · Decided Jul 30, 2026 · 323 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- FoundationOne Liquid CDxPMA supplement
P190032-S029 · Decided May 27, 2026 · 490 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Signatera CDxBreakthroughPMA
P260004 · Decided May 15, 2026 · 106 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S026 · Decided Jan 15, 2026 · 176 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Reports received
7
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
7
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 6 | 0 | 0 | 0 |
| May 26 | 1 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Product Quality Problem6
- False Negative Result1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions7
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Hamilton Microlab STAR Liquid Handler; Protocol Configuration Tool (PCT) v2.0.0. Used to conduct F1CDx and F1LCDx.Open, Classified
Z-2951-2026 · Started Jun 10, 2026 · Posted by FDA Aug 14, 2026
Reason given: Software issue that can cause an increase in spontaneous software closures.
Cause as FDA categorized it: Software design
Z-1937-2026 · Started Mar 24, 2026 · Posted by FDA Apr 23, 2026
Reason given: Potential for spontaneous closures of Hamilton HxRunControl software during execution of Autolys protocols after deployment of the PCT software for AutoLys Hamilton STAR.
Cause as FDA categorized it: Software change control
- Sequencing Agent SEQ0067, component of FoundationOne CDx (F1CDx)Open, Classified
Z-1927-2026 · Started Mar 20, 2026 · Posted by FDA Apr 22, 2026
Reason given: Possible increase in phasing, potentially resulting in false-positive BARD1 splice site indel artifact variants
Cause as FDA categorized it: Under Investigation by firm
Z-2521-2025 · Started Jun 17, 2025 · Posted by FDA Sep 4, 2025
Reason given: Due to an incorrect test results provided that indicated the incorrect drug therapy recommendation
Cause as FDA categorized it: Software design
- FoundationOne Companion Diagnostic (F1CDx)Open, Classified
Z-1747-2025 · Started Apr 9, 2025 · Posted by FDA May 12, 2025
Reason given: Four (4) total reports were sent to customers with clinically relevant variants requiring amendment, one (1) of which with an incorrect negative CDx claim. The remaining three (3) with tumor profiling result changes did not impact CDx indications.
Cause as FDA categorized it: Under Investigation by firm
- FoundationOne Companion Diagnostic (F1CDx)Open, Classified
Z-1890-2025 · Started Jun 18, 2024 · Posted by FDA May 30, 2025
Reason given: Two (2) reports were sent to customers with an incorrect negative claim on the claims page; the device variant information was displayed correctly in the tumor profiling section of both FDA-approved test reports.
Cause as FDA categorized it: Software design
- Agilent Resolution ctDx FIRST Sample Collection Kit, 500032Open, Classified
Z-1358-2023 · Started Feb 17, 2023 · Posted by FDA Apr 11, 2023
Reason given: Distributed sample collection kit with an unapproved instruction for use.
Cause as FDA categorized it: Labeling Change Control
- FoundationOne Companion Diagnostic (F1CDx)Open, Classified
Z-1891-2025 · Started Feb 15, 2023 · Posted by FDA May 30, 2025
Reason given: An incorrect negative claim was identified on the claims page; the device variant information was displayed correctly in the tumor profiling section of the FDA-approved test report.
Cause as FDA categorized it: Software design
Showing the 8 newest of 18 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.